Andere Sprachen Zai Lab Limited BOERSE MUENCHEN

Aktien

A2DX1V

US98887Q1040

1ZL

Realtime BOERSE MUENCHEN Andere Börsenplätze 13:13:39 03.07.2024			% 5 Tage	% 1. Jan.
16 ^EUR	0,00 %		-7,51 %	-34,43 %

27.06.	Zai Lab Insider verkaufte Aktien im Wert von $428.532, laut einer aktuellen SEC Einreichung	MT
20.06.	Zai Lab vergibt ADSs an unabhängige Direktoren im Rahmen eines Incentive-Programms	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	27.06.
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath	21.06.
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	20.06.
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	14.06.
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024	11.06.
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	11.06.
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	04.06.
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24.05.
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22.05.
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22.05.
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22.05.
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21.05.
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	20.05.
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20.05.
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20.05.
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20.05.
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16.05.
Zai Lab Announces Participation in May and June Investor Conferences	16.05.
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14.05.
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	14.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zai Lab Limited BOERSE MUENCHEN

Aktien

A2DX1V

US98887Q1040

1ZL

Andere Sprachen

Filter